RE: Exec Director/Acting CEO21 May 2024 22:38
ED has options at 20p, Xiwang funding package (which we await signoff for) is for equity at 20p, broker targets are averaging around the 50p mark, CFO said based just on reserves the mc should be around the $130m mark, the loan notes convert at 30p per share.
Whichever way you look at it this company is severely undervalued. $150m funding package signoff once legal agreements are signed and political risk insurance policy in place will be the catalyst for the rerate.